Huadong Medicine Company

Huadong Medicine Company is a pharmaceutical enterprise specializing in the research, development, production, and sales of various medicinal products. The company focuses on specialty medicines, chronic disease treatments, antibiotics, proprietary Chinese medicine, chemical synthetic drugs, and genetic engineering products. Additionally, Huadong Medicine is involved in the wholesale and retail distribution of both Chinese and Western medicines, including herbal remedies and medical apparatus. Their product portfolio features a range of medications, including Corbrin capsules, Cymusi, New Cyspin, Kasiping, Panlisu, and Acarbose. The company has established a key technology system for the development and production of microbial drugs, underscoring its commitment to advancing pharmaceutical innovation.

Lv Liang

Chairman

Liang Lu

Chairman

8 past transactions

Chongqing Yuyan

Series B in 2023
Chongqing Yuyan is a biomedical innovation and medical beauty product research and development company. It intends to address the biosafety concerns associated with extracting natural botulinum toxin from the host Clostridium botulinum.

Heidelberg Pharma

Post in 2022
Heidelberg Pharma GmbH, a drug development company, provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology in the fields of oncology or inflammatory/autoimmune diseases.

Heidelberg Pharma

Post in 2022
Heidelberg Pharma GmbH, a drug development company, provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology in the fields of oncology or inflammatory/autoimmune diseases.

Heidelberg Pharma

Post in 2022
Heidelberg Pharma GmbH, a drug development company, provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology in the fields of oncology or inflammatory/autoimmune diseases.

Ashvattha Therapeutics

Series B in 2021
Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.

R2 Technologies

Series B in 2021
R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

R2 Technologies

Series B in 2020
R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

Ningbo Donghai Bank

Angel Round in 1993
Ningbo Donghai Bank offers services for business banking. They collaborate with the corporate culture of implementing sunshine management, forming a sunshine team and business, offering a sunshine service, and creating a sunny brand. They aim to create a business with qualities, values, and compassion a regional bank an enhanced service provider; to make appropriate contributions to the high-quality development of the regional economy and society, and to continuously embark on new endeavors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.